Medicinal composition containing gp34 binding-inhibitor as the active ingredient
AssigneeMitsui Chemicals, Inc.
InventorsKazuo Sugamura, Kazuko Murata, Norikazu Higashimura
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for the therapeutic treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, sarcoidosis, autoimmune uveitis, and inflammatory bowel disease, or graft-versus-host disease. The pharmaceutical composition contains, as the effective ingredient, a gp34 binding-inhibitory substance.
Claims2
A method of treating rheumatoid arthritis comprising administering a monoclonal antibody against a human T-cell leukemia virus-derived transcription activating factor p40Tax-induced cell membrane glycoprotein of 34 kDa (gp34) in an amount effective for treating rheumatoid arthritis to a patient in need of such treatment, wherein said monoclonal antibody inhibits the binding of said human gp34 to human OX40.
A method of treating multiple sclerosis comprising administering a monoclonal antibody against a human T-cell leukemia virus-derived transcription activating factor p40Tax-induced cell membrane glycoprotein of 34 kDa (gp34) in an amount effective for treating multiple sclerosis to a patient in need of such treatment, wherein said monoclonal antibody inhibits the binding of said human gp34 to human OX40.
Dependencies are inferred from the claim text.